TransMedics Sets 2026 Revenue Guidance at $764M-$774M

The forecast includes about $14 million from the recently acquired PAD Aviation business, while comparable guidance excluding it rises to $750 million-$760 million.

Updated on Nov. 7, 2026 in Healthcare

Single unmarked white cargo aircraft parked on an empty airport apron at dawn under a pale blue-grey sky, with long morning shadows across the tarmac. — TransMedics raised its 2026 revenue guidance to $764 million to $774 million, including about $14 million from its recently acquired PAD Aviation business. AI Illustration. Upload story photo >

TransMedics Group set its 2026 revenue guidance at $764 million to $774 million, including approximately $14 million from PAD Aviation. Excluding PAD Aviation, the comparable forecast is $750 million to $760 million, up from the previous range of $737 million to $757 million.

Why it matters

The upward revision to both ends of the comparable range signals stronger expected revenue for the organ transplant logistics company. The company also reported that the third quarter of 2026 was its strongest in history for both revenue and case volume.

Excluding PAD Aviation's approximately $14 million contribution, TransMedics now projects $750 million to $760 million in 2026 revenue, up from $737 million to $757 million previously. The company has not explained in the source what specifically drove the raised comparable range.

The players

TransMedics Group

TransMedics Group is a U.S. medical technology company that develops organ transplant logistics systems, including its OCS platform for transporting donor organs.

PAD Aviation

PAD Aviation is an aviation services business that TransMedics acquired, which contributes approximately $14 million to the company's 2026 revenue guidance.

The details

TransMedics Group, which provides organ transplant logistics technology, set its 2026 revenue guidance at $764 million to $774 million, a range that includes approximately $14 million from its PAD Aviation acquisition. The company said the third quarter of 2026 was its strongest in history for both revenue and case volume.

Third quarter of 2026: Strongest revenue and case volume quarter in company history.
2026: Revenue guidance set at $764 million to $774 million including PAD Aviation.

Market Landscape

TransMedics' OCS organ perfusion platform underpins the company's case volume growth, which drove its record third quarter in 2026. The acquisition of PAD Aviation extends the company's logistics footprint beyond its core technology into aviation transport services.

For patients awaiting organ transplants, improvements in organ transport logistics can affect the timing and availability of donor organs. The company's expanded revenue outlook reflects growing demand for its transplant services, though the source does not describe any direct change to patient costs.

The takeaway

Revenue growth at medical logistics firms like TransMedics often tracks rising transplant activity, making case volume a useful indicator to watch alongside headline guidance. Readers following the sector can compare future quarterly case counts against this record third quarter to gauge whether momentum continues.